Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IIOngoingJul 17, 2013Amikacin Sulfate 250 mg/ml InjectionLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesLowlite Investments, Inc. D/B/A Olympia Pharmacy · D-697-2013Class IIOngoingJul 17, 2013Altrenogest 50 mg/ml InjectionLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesLowlite Investments, Inc. D/B/A Olympia Pharmacy · D-696-2013Class IIOngoingJul 17, 2013Alprostadil 2000 mcg/mlLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesLowlite Investments, Inc. D/B/A Olympia Pharmacy · D-695-2013Class IIOngoingJul 17, 2013Adenosine-Mono-Phosphate InjectionLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesLowlite Investments, Inc. D/B/A Olympia Pharmacy · D-694-2013Class IIOngoingJul 17, 2013Acepromazine 25 mg/ml InjectionLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesLowlite Investments, Inc. D/B/A Olympia Pharmacy · D-693-2013Class IIOngoingJul 17, 2013Acetyl-D-Glucosamine w/Chondroitin 200 mg/mlLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesLowlite Investments, Inc. D/B/A Olympia Pharmacy · D-692-2013Class IIITerminatedJul 17, 2013Nicardipine Hydrochloride Injection 25 mg/10 mLFailed Impurity/Degradation Specifications; out of specification value for impurity Nitrophenylpuridine Derivative (NPP-D)West-ward Pharmaceutical Corp. · D-691-2013Class IIITerminatedJul 17, 2013Camila (norethindrone tabletsFailed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testingTeva Pharmaceuticals USA, Inc. · D-690-2013Class IIITerminatedJul 17, 2013Errin (norethindrone tabletsFailed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testingTeva Pharmaceuticals USA, Inc. · D-689-2013Class IIITerminatedJul 17, 2013Folic Acid InjectionFailed Impurities/Degradation SpecificationFresenius Kabi USA, LLC · D-688-2013Class IITerminatedJul 17, 2013Nimodipine Capsules 30 mgCrystallization; crystallized nimodipineSun Pharmaceutical Industries Inc. · D-687-2013Class IITerminatedJul 17, 2013Gentamicin Sulfate Injection USP 80 mg/2 mLPresence of Particulate Matter: visible particles were identified floating in the primary container.Hospira Inc. · D-686-2013Class IITerminatedJul 17, 2013Benztropine Mesylate InjectionPresence of particulate matter: characterized as thin colorless flakes that are visually and chemically consistent with glass delamination observed in reserve sample...Fresenius Kabi USA, LLC · D-685-2013Class IIITerminatedJul 17, 2013Balziva(TM)Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testingTeva Pharmaceuticals USA, Inc. · D-684-2013Class IIITerminatedJul 17, 2013Jolessa(R)Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testingTeva Pharmaceuticals USA, Inc. · D-683-2013Class IIITerminatedJul 17, 2013Junel(TM) Fe 1.5/30Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testingTeva Pharmaceuticals USA, Inc. · D-682-2013Class IIITerminatedJul 17, 2013Lessina(R)Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testingTeva Pharmaceuticals USA, Inc. · D-681-2013Class IITerminatedJul 10, 2013Vancomycin 50 mg/mlLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesClinical Specialties Compounding Pharmacy · D-680-2013Class IITerminatedJul 10, 2013TetracaineLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesClinical Specialties Compounding Pharmacy · D-679-2013Class IITerminatedJul 10, 2013Test cyp 75 mg-estradiol cyp 5 mg/mlLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesClinical Specialties Compounding Pharmacy · D-678-2013Class IITerminatedJul 10, 2013Test Cyp 50 mg-estradiol blend 22 mgLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesClinical Specialties Compounding Pharmacy · D-677-2013Class IITerminatedJul 10, 2013Test Cyp 50 mg-estradiol cyp 7 mg/mlLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesClinical Specialties Compounding Pharmacy · D-676-2013Class IITerminatedJul 10, 2013Test Cyp 50 mg-estradiol cyp 2 mg/mlLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesClinical Specialties Compounding Pharmacy · D-675-2013Class IITerminatedJul 10, 2013Test Cyp 50 mg-estradiol cyp 2 mg/mlLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesClinical Specialties Compounding Pharmacy · D-674-2013Class IITerminatedJul 10, 2013Test cyp 50 mg/mlLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesClinical Specialties Compounding Pharmacy · D-673-2013Class IITerminatedJul 10, 2013Test cyp 35 mg/mlLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesClinical Specialties Compounding Pharmacy · D-672-2013Class IITerminatedJul 10, 2013Test Cyp 25 mg-eLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesClinical Specialties Compounding Pharmacy · D-671-2013Class IITerminatedJul 10, 2013Test cyp 25 mg-estradiol cyp 7 mg/mlLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesClinical Specialties Compounding Pharmacy · D-670-2013Class IITerminatedJul 10, 2013Test Cyp 250 mg-lidocaine 5 mg/mlLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesClinical Specialties Compounding Pharmacy · D-669-2013Class IITerminatedJul 10, 2013Test cyp 25 mg-Estradiol cyp 5 mg/mlLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesClinical Specialties Compounding Pharmacy · D-668-2013Class IITerminatedJul 10, 2013Test cyp 25 mg-Estadiol valerate 15 mg/mLLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesClinical Specialties Compounding Pharmacy · D-667-2013Class IITerminatedJul 10, 2013Test Cyp 200 mg/mlLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesClinical Specialties Compounding Pharmacy · D-666-2013Class IITerminatedJul 10, 2013Test Cyp 100 mg/mlLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesClinical Specialties Compounding Pharmacy · D-665-2013Class IITerminatedJul 10, 2013Test Cyp 10 mg/mlLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesClinical Specialties Compounding Pharmacy · D-664-2013Class IITerminatedJul 10, 2013Sodium ChlorideLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesClinical Specialties Compounding Pharmacy · D-663-2013Class IITerminatedJul 10, 2013Progesterone 50 mg/mlLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesClinical Specialties Compounding Pharmacy · D-662-2013Class IITerminatedJul 10, 2013Phenylephrine-cyclopentolateLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesClinical Specialties Compounding Pharmacy · D-661-2013Class IITerminatedJul 10, 2013Pap 300 mg-phent 10 mg-prost 100 mcgLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesClinical Specialties Compounding Pharmacy · D-660-2013Class IITerminatedJul 10, 2013Ophthalmic dilation gelLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesClinical Specialties Compounding Pharmacy · D-659-2013Class IITerminatedJul 10, 2013Ophthalmic dilation gelLack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processesClinical Specialties Compounding Pharmacy · D-658-2013

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.